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Abstract 
Purpose: The purpose of this article is to describe how an innovative partnership between a rural community mental health center, 
community independent pharmacy and College of Pharmacy and integration of a mental health pharmacist lead to identification of 
medication therapy problems (MTP’s) and interprofessional team partnerships with center mental health professionals.  
Methods: A contractual arrangement was initiated between Northern Pines Mental Health Center (NPMHC), GuidePoint Pharmacy 
Services GPS) and the University of Minnesota College of Pharmacy (UMN CoP) to place a PGY1 resident at NPMHC.  The resident was 
assigned to work closely with the Chief Medical Officer and provide initial comprehensive medication management (CMM) services to 
individuals who were enrolled in Assertive Community Treatment (ACT). A retrospective chart review was conducted to evaluate the 
impact of services provided. Patient inclusion criteria included ACT enrollees 18 years or older, a diagnosis of SPMI, taking at least one 
psychotropic medication, and participation in at least one resident-led CMM visit. Additional findings included the relationship between 
the pharmacist, the psychiatric physician, and other members of the ACT team. Descriptive statistics were used to document the findings. 
Findings: N = 30 met the inclusion criteria: 18 males and 12 females, age ranged from 24 - 69 with average of 44 years old. 110 MTPs 
were identified ranging from no MTPs to 10 MTPs per patient, with a mean of 4 MTPs/patient. There was an uneven distribution of MTPs 
between psychiatric and medical conditions, with a disproportionately high occurrence of “Needs Additional Drug Therapy” in medical 
conditions and “Adverse Drug Reaction” in psychiatric conditions. In addition, the services were valued by members on the ACT team. 
Conclusion: Rural residents with SPMI in intensive community treatment have complex medication needs that require the training and 
skills of a clinical pharmacist. Despite the inclusion of a medication list as part of the ACT fidelity standards MTPs may go unrecognized 
and unresolved without the services of a clinical pharmacist conducting CMM. The pharmacist and psychiatric physician formed a 
collaborative partnership to address medication issues. We conclude that there is a need for integrating clinical pharmacist services into 
rural mental health centers. 
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The national burden of mental health and substance use 
disorders is significant and rural areas are affected 
disproportionately. Access to care is a nationally recognized 
barrier to receiving mental health services and this problem is 
most prominent among rural communities. The U.S. Health 
Resources & Services Administration (HRSA) reported that there 
were 3,669 mental health Health Professional Shortage Areas 
(HPSAs) containing almost 91 million people in the past year. It 
would take 1,846 psychiatrists and 5,931 other practitioners to 
fill the needed slots1. For instance, in Minnesota (MN) all regions 
other than the Twin Cities metro area have been designated as 
mental health HPSAs. Another concern is that the aging of 
existing mental health workforce. The median age of U.S. 
psychiatrists is 55.7 years, with 46% over the age of 65 years.     
The same trend is seen among     social workers1 and addiction 
treatment service providers, exacerbated by high workforce 
turnover rate2. It is vital to fortify the existing behavioral health 
workforce to extend access to quality care.                                                                                                              
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Another challenge in providing optimal care for patients living 
with mental health and substance use disorders is the 
fragmentation of care. Adults living with a serious mental illness 
(SMI) are at increased risk for having comorbid chronic medical 
conditions. On average persons with SMI die 25 years earlier, due 
to these treatable medical conditions3. These patients are often 
found to be affected by a significant health disparity due to the 
continued lack of adequate integration of care between 
psychiatry and primary care. It has been well-established that 
these patients often fall through the cracks of metabolic 
monitoring, not only because of consequences of their mental 
illness leading to missed appointments and lower adherence to 
medications, but also due to the lack of regular connection with 
a primary care provider4.  
 
Pharmacists are well positioned to bridge primary care and 
psychiatric care and also fill the rural workforce shortage in a cost 
effective manner. Given that a majority of patients with mental 
illnesses have several comorbid medical conditions, complex 
medication regimens with significant negative side effect profiles 
and poor treatment adherence, pharmacists can help in 
optimizing outcomes5. Comprehensive clinical pharmacist 
activities include medication evaluation and monitoring, 
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optimization of medication regimens, therapeutic 
recommendations, laboratory test ordering and interpretation, 
prescribing authority under collaborative protocols with 
physicians, patient education, education of behavioral health 
staff including prescribers, and consultation services6. There have 
been several past examples of successful incorporation of clinical 
pharmacy services within mental health and substance use 
disorders care teams7,8,9,10,11,12 (Bell et al 2005; Bell et al 2007, 
Chen 2001; Chen 2007; Finley et al 2003; Richardson et al 2014). 
Services provided by a psychiatric pharmacist working within a 
health care home model resulted in a 2.8:1 return on 
investment13. Other studies have proven the value of a 
pharmacist by showing an improvement in adherence to 
metabolic monitoring guidelines for patients receiving second-
generation antipsychotics14, achievement of response to 
pharmacotherapy in patients with comorbid depression and 
diabetes15, improvement in functioning and decreased overall 
severity of illness16, and decreased hospital readmission within 
30 days17.  
 
To our knowledge, there have been no reports or studies of 
partnerships that have integrated a clinical pharmacist into rural 
community mental health centers. Therefore, we describe the 
unique partnership and care model implemented in a rural 
Minnesota mental health center.  
 
Methods 
Care Model Partnership and Implementation 
Recognizing a need for more accessible, comprehensive, 
affordable, and high quality psychiatric care in rural Minnesota, 
the University of Minnesota College of Pharmacy spearheaded an 
innovation in pharmacy practice to address this need. The 
College started a post-doctoral Postgraduate Year-1 (PGY-1) 
Pharmacy Residency program with a concentration in mental 
health by partnering with GuidePoint Pharmacy and Northern 
Pines Mental Health Center (NPMHC) in Brainerd, MN. Through 
this program, a PGY-1 pharmacy resident was incorporated into 
the NPMHC Assertive Community Treatment (ACT) 
multidisciplinary care team. 
 
The pharmacy resident (SN) functioned as a member of the ACT 
team and traveled to patients’ homes to provide Comprehensive 
Medication Management (CMM) services, in addition to point-
of-care-testing services as indicated. Provision of CMM is in 
adherence to the Pharmacists’ Patient Care Process as defined by 
the Joint Commission of Pharmacy Practitioners (JCPP) where 
each medication (prescription or over-the-counter), nutritional 
supplement, or other treatment is assessed for appropriate 
indication, effectiveness, safety concerns, and barriers to 
adherence. The pharmacy resident worked with the patients and 
their respective NPMHC and non-NPMHC providers, which 
includes primary care as well as other specialists to 
collaboratively manage the often complex medication regimens 
in this population. Resident supervision was consistently 
provided by clinical preceptors at GuidePoint Pharmacy and 
College of Pharmacy. 
Assessment of Care Model 
A retrospective chart review was conducted by the pharmacy 
resident and collaborating psychiatric physician. Inclusion 
criteria: ACT program enrollees 18 years and older, diagnosis of a 
Serious and Persistent Mental Illness (SPMI), taking at least one 
psychotropic medication, and participation in at least one 
pharmacy resident-led CMM visit from July 2016 to April 2017. 
Primary outcome measures are the number and type of MTPs. 
Secondary outcomes investigated are the number of MTPs in 
psychiatric and medical illnesses. Additional care model 
anecdotal results including provider well-being and job 
satisfaction were recorded. Deidentified data was recorded with 
Microsoft Excel and stored securely in agency-issued secured 
laptop. The analyses of the deidentified data were exempt from 
consent by the institutional review board of the University of 
Minnesota (ETHOS ID: 152). 
 
Results 
Thirty patients met the inclusion criteria: 18 males and 12 
females with an average age of 44 years old (ranged from 23 - 69 
years old). Nineteen patients had a diagnosis of schizophrenia, 
eight with bipolar disorder and three with major depressive 
disorder (Table 1). All patients had comorbid medical or mental 
illnesses including substance use disorders and high use of 
tobacco and caffeine (Table 1). 
 
Table 1. Diseases Background 
Principal Psychiatric Diagnosis N (%) 
Schizophrenia 19 (63) 
Bipolar Disorder 8 (27) 
Depression 3 (10) 
Comorbid Conditions   
Depression 6 (20) 
Anxiety 12 (40) 
Substance Use Disorder 8 (27) 
Hypertension 6 (20) 
Diabetes Mellitus 7 (23) 
Dyslipidemia 9 (30) 
Pain 10 (33) 
COPD 3 (10) 
Lifestyle   
Tobacco 23 (77) 
Alcohol 11 (37) 
Caffeine 27 (90) 
Illicit Drugs 6 (20) 
 
Using standard pharmacist CMM process, 110 medication 
therapy problems (MTPs) were identified ranging from no 
medication therapy problems per patient to as many as 10 
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medication therapy problems per patient, and a mean of 4 MTPs 
per patient. One patient did not have any identified MTPs during 
this specified timeframe. The most frequent MTP was Needs 
Additional Drug Therapy. This was due to a number of factors but 
most often related to a need for preventive immunizations which 
had not been administered and the need for cardiovascular event 
preventative therapy (Figure 1).  
 
Figure 1. Types of Medication Therapy Problems 
 
 
The average number of conditions being treated per patient in 
this group was 5.7 (range from 1 - 13 conditions per patient). The 
average number of medications taken per patient in this group 
was 9.6 (range from 1 - 24 medications per patient). The plotted 
graph (Figure 2) with total number of medications taken per 
patient on the x-axis and the corresponding total number of 
MTPs on the y-axis does not appear to indicate that there is a 
correlation between medication burden and burden of 
medication therapy problems.  
 
Figure 2. Correlation between Medication Burden and 
Medication Therapy Problems 
 
 
Distribution of MTPs was different when comparing psychiatric 
medication MTP’s to medical MTP’s. Psychiatric medications 
were often associated with a lack of indication and adverse 
events while medications for medical conditions were associated 
with lack of effectiveness or the need for additional therapy to 
reach treatment goals (Figure 3). 
Figure 3. Distribution of Medication Therapy Problems in 
Psychiatric and Medical Conditions 
 
 
Other incidental findings were the acceptance and value placed 
on the pharmacist resident by the patients, ACT staff and the 
chief medical officer psychiatrist. 
 
Discussion 
Adhering to Comprehensive Medication Management and the 
Pharmacists’ Patient Care Process by the Joint Commission of 
Pharmacy Practitioners18 is becoming the community standard of 
practice for pharmacist provision of direct-patient care services. 
In its published final form, The Joint Commission of Pharmacy 
Practitioners expanded the definition of these services: 
“Medication management services are a spectrum of patient-
centered, pharmacist-provided, collaborative services that focus 
on medication appropriateness, effectiveness, safety, and 
adherence with the goal of improving health outcomes.” 
 
The Assertive Community Treatment (ACT) care model is one of 
the most widely researched evidence-based practices in 
community behavioral healthcare for people with SMI19. It has 
been shown to improve outcomes for people with SMI who are 
most at-risk for psychiatric crises, hospitalizations, and 
involvement with the criminal justice system. A multidisciplinary 
team approach is adopted to provide a comprehensive, assertive 
treatment approach, which encompasses physical health and 
behavioral health issues in the SMI population. For 
standardization of the practice of the model, ACT teams are 
required to adhere to the ACT fidelity standards developed and 
refined over the years. In Minnesota, ACT teams adhere to the 
TMACT (Tool for Measurement of Assertive Community 
Treatment) developed by Monroe-DeVita and colleagues20. 
 
At NPMHC, the clinical pharmacy resident in collaboration with 
the attending psychiatric physician became the medication 
expert within the ACT team, monitoring the patients closely and 
making diagnostic assessments for drug-drug interactions and 
potential medication side effects, performed therapeutic drug 
monitoring, assessed organ functions through interpretation of 
laboratory values, and monitored improvements in the chronic 
disease states. In so doing, the clinical pharmacist was best 
positioned to uphold the biomedical fidelity standards nestled     
in the psychosocial care and ACT framework within a community 
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mental health center. Another service included 
medication/disease state education to the patients and their 
caregivers. An important and unique role for the clinical 
pharmacist in the mental health care system, which operations 
are often siloed, was to serve as the clinical care coordinator and 
primary care expert to ensure patients’ chronic medical 
conditions and preventative care were optimally managed. The 
retrospective chart review revealed a high burden of medication 
therapy problems in this population that was previously not 
identified by other healthcare professionals involved with the 
patients’ care. This observation further supports findings from 
existing literature of such health disparity amongst persons with 
SPMIs.  
 
The statutes governing the fidelity standards for ACT medication 
management have delegated primary responsibility to the 
nursing staff. However, in this case and in others it is apparent 
that the complexity of these patients requires a professional with 
additional training and skills as demonstrated by other 
studies4,5,13. While nurse provided care may be effective for 
developing a medication list, arranging medication times, and 
addressing adherence issues, there is no comprehensive 
diagnostic assessment of medication therapy problems. Our 
results support this issue of complexity and the potential missed 
opportunities to address gaps in actual medication therapy. One 
of the most striking issues uncovered in this ACT group was the 
Needs Additional Therapy category, examples of which ranged 
from immunizations, statin therapy in patients with diabetes, to 
nicotine replacement therapy for tobacco cessation. Under 
psychiatric indications, Adverse Drug Reactions was the most 
common MTP, with notable incidences of extrapyramidal 
symptoms, metabolic abnormalities, and anticholinergic effects. 
 
Indirect patient care services provided by the clinical pharmacist 
included formulary management, assistance with prior 
authorizations, and prescription assistance programs. Regular 
clinical pharmacist in-services were launched within NPMHC to 
keep providers abreast of updates in practice, not just in mental 
health care, but primary care as well. 
 
The ability of ACT staff to meet the patients where they reside in 
the community setting continues to be the fundamental guiding 
principle of the ACT care model. With the integration of the 
pharmacy resident into the ACT team, the ability to deliver some 
of the clinical patient care services at patients’ homes allowed 
increased accessibility to qualified professionals in the setting of 
persons disadvantaged by multi-layered socioeconomic factors 
that plague rural populations. In a survey published by Minnesota 
Department of Health – Health Economics Program and Office of 
Rural Health & Primary Care, results showed insurance coverage 
disparities decreased across racial groups and between rural-
urban areas, however rural Minnesotans were still significantly 
more likely than their urban counterparts to have difficulties 
paying healthcare bills and experience greater challenge in 
getting a timely appointment with primary care providers21. 
Social determinants of mental health, further compounded by 
barriers in rural geographic areas including limited transportation 
options, limited broadband internet access, and higher poverty 
rates – may not seem relevant to clinical pharmacy practice at 
first glance. However, visits performed at patients’ homes allow 
the clinical pharmacist to adopt a holistic approach to CMM in 
considerations of actual medication-taking behavior of the 
patients at home and further allow the clinical pharmacist to 
provide patient-centered medication recommendations. 
              
One benefit that emerged from incorporating clinical pharmacist 
services at NPMHC is the improved workload distribution among 
care team members. The collaborating psychiatric physician 
reported more efficient clinic flow and being able to serve 
additional patients due to pre-identified medication therapy 
problems and recommendations that may be targeted during the 
psychiatric visits. Other team members reported improved 
understanding of medications and adverse effects, thereby 
improved triage and timely communication with pertinent 
providers. 
 
NPMHC management and clinical staff were so pleased with the 
results that they subsequently hired the clinical pharmacy 
resident as their full time clinical pharmacist.  The 3-way 
partnership continues with GuidePoint Pharmacy providing the 
third year of residency support in collaboration with NPMHC and 
the College of Pharmacy.  
 
Limitations 
As a retrospective chart review, this study did not include a 
control group and it also has a small number of patients 
concentrating on a specific end on a wide spectrum of mental 
illnesses and severity levels. Therefore, it warrants further 
investigation to ascertain the landscape of medication therapy 
problems in other patient populations or non-pharmacist-led 
CMM.  
 
Conclusion  
The establishment of clinical pharmacy services through a multi-
organization partnership mental health focused PGY-1 Pharmacy 
Residency program within an ACT team in rural Northern 
Minnesota has been successful on several levels. It has 
demonstrated the value of CMM provided by a pharmacist in the 
mental health setting, underscored the enormous value of 
collaboration and coordination of care on clinical gaps in care, 
and highlighted the critical importance of professional 
relationship-building in creating new models of care. These 
benefits should not be overlooked as new opportunities for 
pharmacists to expand their roles in mental health and SUDs are 
pursued. Looking into the future, there are numerous 
opportunities for pharmacists to make a difference in providing 
care to rural residents with SMI. Creating interprofessional 
alliances like the relationships established at NPMHC is the first 
step in our shared vision of a rural care model.  
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